Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

The pharmacokinetics of 12-week continuous contraceptive patch use.

Lavelanet AF, Rybin D, White KO.

Contraception. 2017 Jun;95(6):578-585. doi: 10.1016/j.contraception.2017.03.002. Epub 2017 Mar 8.

PMID:
28285154
2.

Transdermal contraception methods: today's patches and new options on the horizon.

Nelson AL.

Expert Opin Pharmacother. 2015 Apr;16(6):863-73. doi: 10.1517/14656566.2015.1022531. Review.

PMID:
25800084
3.

A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.

Gruber D, Skřivánek A, Serrani M, Lanius V, Merz M.

Contraception. 2015 Feb;91(2):105-12. doi: 10.1016/j.contraception.2014.10.003. Epub 2014 Oct 13.

PMID:
25453582
4.

Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.

Hofmann B, Reinecke I, Schuett B, Merz M, Zurth C.

Int J Clin Pharmacol Ther. 2014 Dec;52(12):1059-70. doi: 10.5414/CP202064.

5.

Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: a prospective study.

Hernandez-Juarez J, Garcia-Latorre EA, Moreno-Hernandez M, Moran-Perez JF, Rodriguez-Escobedo MA, Cogque-Hernandez G, Julián-Nacer R, Hernandez-Giron X, Palafox-Gomez R, Isordia-Salas I, Majluf-Cruz A.

Reprod Health. 2014 Apr 26;11:33. doi: 10.1186/1742-4755-11-33.

6.

Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.

Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R.

Antivir Ther. 2014;19(5):511-9. doi: 10.3851/IMP2718. Epub 2013 Dec 17.

PMID:
24343001
7.

Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users.

Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP Jr, Cooper WO.

Contraception. 2013 Jan;87(1):93-100. doi: 10.1016/j.contraception.2012.09.015. Epub 2012 Oct 19.

PMID:
23083525
8.

Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective.

Raymond EG, Burke AE, Espey E.

Obstet Gynecol. 2012 May;119(5):1039-44. doi: 10.1097/AOG.0b013e31825194ca.

PMID:
22525916
9.

Allergic contact dermatitis caused by an ethinylestradiol-norelgestromin transdermal therapeutic system.

Alfaya T, Mur Gimeno P, Iglesias AM, Ventura P.

Contact Dermatitis. 2011 Apr;64(4):242-4. doi: 10.1111/j.1600-0536.2011.01880.x. No abstract available.

PMID:
21392036
10.

High levels of women's satisfaction and compliance with transdermal contraception: results from a European multinational, 6-month study.

Jakimiuk AJ, Crosignani PG, Chernev T, Prilepskaya V, Bergmans P, Von Poncet M, Marelli S, Lee EJ.

Gynecol Endocrinol. 2011 Oct;27(10):849-56. doi: 10.3109/09513590.2010.538095. Epub 2010 Dec 10.

11.

[Combined hormonal contraception in cycles artificially extended].

Bustillos-Alamilla E, Zepeda-Zaragoza J, Hernández-Ruiz MA, Briones-Landa CH.

Ginecol Obstet Mex. 2010 Jan;78(1):37-45. Spanish.

PMID:
20931801
12.

Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study.

Massaro M, Di Carlo C, Gargano V, Formisano C, Bifulco G, Nappi C.

Contraception. 2010 Mar;81(3):209-14. doi: 10.1016/j.contraception.2009.09.011. Epub 2009 Oct 29.

PMID:
20159176
13.

Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.

Schwartz JI, Liu F, Wang YH, Pramanik B, Johnson-Levonas AO, Gutierrez MJ, Lai E, Wagner JA.

Am J Ther. 2009 Nov-Dec;16(6):487-95. doi: 10.1097/MJT.0b013e3181985130.

PMID:
19940609
14.

Effect of the ethinylestradiol/norelgestromin contraceptive patch on body composition. Results of bioelectrical impedance analysis in a population of Italian women.

Piccoli A, Crosignani P, Nappi C, Ronsini S, Bruni V, Marelli S; Italian EVRA Contrast Study Group.

Nutr J. 2008 Aug 26;7:21. doi: 10.1186/1475-2891-7-21.

15.

A clinical study of transdermal contraceptive patch in Thai adolescence women.

Piyasirisilp R, Taneepanichskul S.

J Med Assoc Thai. 2008 Feb;91(2):137-41.

PMID:
18389975
16.

Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial.

Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S, Cushman M.

Obstet Gynecol. 2008 Feb;111(2 Pt 1):278-84. doi: 10.1097/AOG.0b013e3181626d1b.

PMID:
18238963
17.

A clinical study of transdermal contraceptive patch in Thai women.

Suwanmalee O, Taneepanichskul S.

J Med Assoc Thai. 2006 Oct;89 Suppl 4:S1-4.

PMID:
17726805
18.

Transdermal hormonal contraception: benefits and risks.

Burkman RT.

Am J Obstet Gynecol. 2007 Aug;197(2):134.e1-6.

PMID:
17689623
20.

[Safety evaluation of a transdermal contraceptive system with an oral contraceptive].

Radowicki S, Skórzewska K, Szlendak K.

Ginekol Pol. 2005 Nov;76(11):884-9. Polish.

PMID:
16566363

Supplemental Content

Loading ...
Support Center